Terms: = Ovarian cancer AND CEBPA, CEBP, 1050, C/EBP-alpha, P49715 AND Diagnosis
4 results:
1. Point-of-care testing: a disposable label-free electrochemical CA125 and HE4 immunosensors for early detection of ovarian cancer.
Bilgi Kamaç M; Altun M; Yılmaz M; Yılmaz Aktan A; Aktan S; Sezgintürk MK
Biomed Microdevices; 2023 May; 25(2):18. PubMed ID: 37140852
[TBL] [Abstract] [Full Text] [Related]
2. De novo myeloid sarcoma mimicking gynecological tumors: a retrospective case series of eight patients.
Gu Y; Zheng H; Mo S; Guo T; Chen L; Yang J; Xiang Y
BMC Womens Health; 2023 Mar; 23(1):141. PubMed ID: 36978050
[TBL] [Abstract] [Full Text] [Related]
3. Biomarkers and Strategies for Early Detection of ovarian cancer.
Bast RC; Lu Z; Han CY; Lu KH; Anderson KS; Drescher CW; Skates SJ
Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2504-2512. PubMed ID: 33051337
[TBL] [Abstract] [Full Text] [Related]
4. Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: a tangible union against chemoresistant cancer.
Singh PP; Joshi S; Russell PJ; Nair S; Khatri A
BMC Cancer; 2011 Aug; 11():368. PubMed ID: 21861932
[TBL] [Abstract] [Full Text] [Related]
